CD274 and melanoma: Moreover, the combination of atezolizumab, an anti-PD-L1 inhibitor, with the vascular endothelial growth factor receptor (VEGFR) monoclonal antibody bevacizumab demonstrated a favorable ORR of 36.4% and a tolerable safety profile in patients with advanced melanoma (113).